Accurate Prediction of Central Conventional Chondrosarcoma Risk and Outcome Using Methylation Profiling: CHROME.
Summary
Prognostication and clinical management of central conventional chondrosarcomas are challenging due to their heterogeneous behavior and the high interobserver variability of histological grading. This study investigated the prognostic value of DNA methylation profiling to improve risk stratification. Using methylation data from 69 primary tumors, a LASSO Cox regression model identified eight informative methylation sites. These sites were used to construct a risk score, named CHROME, which predicts disease recurrence, onset of metastasis, and disease-specific mortality. Validated in an independent cohort of 68 patients, CHROME demonstrated strong discriminatory performance, accurately stratifying patients into High or Low risk groups.
Analysis
Clinique: This study introduces CHROME, a methylation-based risk score, which provides accurate prognostic stratification for central conventional chondrosarcomas. By overcoming the interobserver variability of current histological grading, CHROME has the potential to transform clinical management by more reliably identifying patients at high or low risk of recurrence, metastasis, and mortality. This could justify clinical trials to tailor therapeutic strategies (e.g., increased surveillance or more aggressive treatments) based on molecular risk profiles, with a potential clinical impact within 3-5 years. Biomol: The discovery of eight specific methylation sites, identified through DNA profiling using Illumina's Human MethylationEPIC Array (850k sites), represents a novel prognostic biomarker. These markers, combined into the CHROME score, enable molecular classification of chondrosarcomas. The use of methylation data from primary tumor samples suggests a potential application in surgical pathology for a diagnostic test complementary to histology, improving diagnostic and prognostic accuracy. Bioinfo: The development of the CHROME score relies on a robust bioinformatics approach, utilizing a LASSO Cox regression model applied to methylation data. This model allowed for the selection of an optimal set of eight informative sites from thousands, reducing complexity and increasing the biomarker's robustness. Validation in an independent cohort (n=68) demonstrates the model's generalizability and discriminatory performance. This type of computational tool could be integrated into clinical workflows to automate and standardize risk assessment, complementing or replacing subjective evaluations.